Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 15, 2024Cancer Research

Abstract A031: Identification of therapeutic vulnerabilities in the subset of pancreatic ductal adenocarcinoma (PDAC) with homologous recombination deficiency

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMathias TessonKKKay KongPRPeter Repsicak

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tesson et al. (2024) studied this question.

synapsesocial.com/papers/68e587f4b6db643587524399https://doi.org/10.1158/1538-7445.pancreatic24-a031
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract B093: Investigating mechanisms of PARP inhibitor resistance in homologous recombination deficient PDAC using patient-derived organoid models2025
  2. 2Abstract 240: Allele-specific sensitization of pancreatic ductal adenocarcinoma to PARP inhibition via adenine base editing.2026
  3. 3Abstract B047: DNA Damage Repair (DDR) Variants Beyond BRCA/PALB2 in Pancreatic Adenocarcinoma (PDAC): Evaluation of Significance2025
  4. 4Abstract 1580: Investigating the tumor microenvironment of pancreatic ductal adenocarcinoma with BRCA2 mutation2024
  5. 5Abstract A125: Tumor cell plasticity, stromal rewiring, and clonal T cell expansion define response and resistance to combined PARP and PD-1 blockade (POLAR) in pancreatic cancer2025